Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APALUTAMIDE vs ANDRODERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Apalutamide is a nonsteroidal antiandrogen that inhibits androgen receptor (AR) nuclear translocation, DNA binding, and transcription of AR target genes. It also decreases AR-mediated tumor cell proliferation and increases apoptosis.
Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.
Metastatic castration-sensitive prostate cancer (m CSPC),Non-metastatic castration-resistant prostate cancer (nm CRPC)
FDA-approved: testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). Off-label: delayed puberty in males, female-to-male transgender hormone therapy.
240 mg orally once daily with or without food.
Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.
Terminal elimination half-life is approximately 3 days (72 hours) for apalutamide and 3–5 days for the active metabolite N-desmethyl-apalutamide. The long half-life supports once-daily dosing and requires approximately 2–3 weeks to reach steady state.
Terminal elimination half-life is approximately 10–100 minutes (rapid), but due to transdermal absorption, effective half-life is extended to about 8–10 hours after patch application.
Primarily metabolized by CYP2C8 and CYP3A4 to active metabolite N-desmethylapalutamide. Also involves glucuronidation by UGTs.
Testosterone is metabolized primarily in the liver via CYP3A4 and CYP2C9 isoenzymes, as well as by 5α-reductase to dihydrotestosterone (DHT) and by aromatase to estradiol.
Apalutamide and its active metabolite N-desmethyl-apalutamide are eliminated primarily via hepatic metabolism and subsequent fecal excretion. Approximately 65% of the dose is recovered in feces (as unchanged drug and metabolites) and 24% in urine (primarily as metabolites). Renal excretion of unchanged drug is negligible.
Approximately 90% of testosterone metabolites are excreted in urine as glucuronide and sulfate conjugates; 6% are excreted in feces via bile.
Apalutamide is highly protein bound (>96%), primarily to albumin and alpha-1-acid glycoprotein. No significant displacement interactions are expected with other highly bound drugs.
Approximately 98–99% bound: primarily to sex hormone-binding globulin (SHBG, ~40%) and albumin (~60%).
Apparent volume of distribution (Vd/F) is approximately 200 L (2.7 L/kg for a 70 kg adult), indicating extensive distribution into tissues including the prostate and other androgen-responsive organs.
Volume of distribution is approximately 0.2–0.8 L/kg, reflecting distribution into steroid-sensitive tissues and binding proteins.
Oral bioavailability is not precisely determined due to lack of an intravenous formulation, but absorption is at least 90% based on mass balance studies. Food does not significantly affect absorption, so it can be taken with or without food.
Transdermal bioavailability is approximately 10–15% of the nominal dose (based on 24-hour application), with interindividual variability due to skin permeability.
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). For severe renal impairment (e GFR 15-29 m L/min), use with caution; no specific dose recommendation. Not studied in end-stage renal disease (e GFR <15 m L/min) or on hemodialysis.
No specific dose adjustment recommended for renal impairment. Use with caution in patients with severe renal impairment due to potential fluid retention.
Mild hepatic impairment (Child-Pugh A): No dose adjustment. Moderate hepatic impairment (Child-Pugh B): Reduce dose to 120 mg once daily. Severe hepatic impairment (Child-Pugh C): Not recommended due to lack of data.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment guidelines.
Safety and efficacy not established; no approved pediatric dosing.
Not indicated for use in pediatric patients. Safety and efficacy have not been established in children <18 years.
No specific dose adjustment required; consider comorbidities and potential for increased adverse effects based on renal and hepatic function.
Initiate at 2.5 mg once daily in elderly patients due to increased risk of adverse effects, particularly prostatic hyperplasia and cardiovascular events. Monitor serum testosterone levels and adjust as needed.
None.
WARNING: Cardiovascular risk - Increased risk of myocardial infarction, stroke, and cardiovascular death has been reported with testosterone replacement therapy. Only use in men with confirmed hypogonadism.
Seizures: Discontinue permanently if seizure occurs during treatment.,Fractures and Falls: Increased risk of bone fractures and falls; assess bone density and manage accordingly.,Cardiovascular Events: Increased risk of hypertension, cardiac ischemia, and heart failure; monitor cardiovascular status.,Hypothyroidism: Monitor thyroid function before and during treatment; replacement therapy may be needed.,Embryo-Fetal Toxicity: Can cause fetal harm; advise males with female partners of reproductive potential to use effective contraception.
Elderly patients and those with known cardiovascular risk factors should be monitored for cardiovascular events.,May exacerbate sleep apnea in predisposed individuals.,Can cause erythrocytosis; monitor hematocrit.,May accelerate growth of prostate cancer and benign prostatic hyperplasia; monitor prostate-specific antigen (PSA).,Monitor for signs of virilization in women if used off-label.,Possible hypercalcemia in immobilized patients.
Pregnancy (can cause fetal harm),Women of reproductive potential (unless using effective contraception)
Men with carcinoma of the breast or known or suspected carcinoma of the prostate.,Women who are pregnant or may become pregnant (risk of virilization of fetus).,Hypersensitivity to testosterone or any component of the product.,Severe renal or hepatic impairment (risk of fluid retention).
Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction. No other specific dietary restrictions; can be taken with or without food.
No known food interactions. Take with or without food.
Apalutamide is contraindicated in pregnancy. Based on its mechanism of androgen receptor inhibition, it may cause fetal harm, including feminization of male fetuses and developmental abnormalities. Adequate animal reproduction studies have not been conducted; however, in rats, fetal malformations were observed at exposures below human clinical exposures. Effective contraception is required for females of reproductive potential during treatment and for 3 months after the last dose.
Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, clitoromegaly) with androgen exposure during critical period of genital differentiation (weeks 8-12). Second and third trimesters: risk of clitoral enlargement, advanced bone age, and potential long-term behavioral effects. Male fetuses may experience premature sexual development. No adequate studies; USP pregnancy category X.
It is unknown whether apalutamide or its metabolites are excreted in human milk. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 3 months after the last dose. M/P ratio is not available.
Testosterone is excreted into human milk; M/P ratio not established. Potential for virilization of female infants and early puberty in male infants. Risk of suppression of maternal lactation (androgen-induced decrease in prolactin). Contraindicated during breastfeeding; alternative therapies recommended.
No dosing adjustments have been established for pregnancy. Apalutamide is not indicated for use in pregnant women. Physiological changes in pregnancy may alter pharmacokinetics, but no data are available to guide dose modifications.
Androderm is contraindicated in pregnancy; no dose adjustments applicable. If therapy is necessary for maternal hypogonadism, discontinue immediately upon pregnancy recognition. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication. Do not dose in pregnancy.
Apalutamide is an androgen receptor inhibitor used for non-metastatic castration-resistant prostate cancer (nm CRPC). It is a strong CYP3A4 inducer and moderate CYP2C8 inhibitor, requiring careful management of drug interactions. Monitor thyroid function and blood pressure. Concomitant use with warfarin or other anticoagulants may necessitate increased monitoring due to reduced efficacy. Apalutamide can cause seizures; avoid in patients with history of seizure disorders. Baseline and periodic serum lipid profiles and glucose levels are recommended. Dose reduction in severe hepatic impairment (Child-Pugh C) is suggested.
Apply to clean, dry, intact skin on the abdomen, thighs, upper arms, or back. Rotate application sites to minimize skin reactions. Do not apply to genitals or scrotum. Avoid showering or swimming for at least 3-4 hours after application to ensure absorption. Monitor serum testosterone levels 14 days after starting therapy or dose adjustment, drawn in the morning before application. Use with caution in patients with known or suspected prostate cancer or breast cancer. Warn patients about the risk of transfer to women and children through skin contact; cover application site with clothing or wash skin before contact.
Take apalutamide with or without food, at the same time each day.,Do not crush, chew, or split tablets; swallow whole.,Avoid grapefruit and grapefruit juice during treatment.,Report signs of seizure, high blood pressure, or thyroid abnormalities to healthcare provider immediately.,Use effective contraception during treatment and for 3 months after last dose; apalutamide may reduce hormonal contraceptive effectiveness.,Inform all healthcare providers of apalutamide use due to potential drug interactions.,May cause fatigue, dizziness, or hot flashes; avoid driving if affected.,Store at room temperature away from moisture and heat.
Apply the gel to clean, dry, intact skin once daily in the morning.,Rotate application sites to prevent skin irritation.,Avoid direct skin contact with women and children; wash hands thoroughly after application and cover the site with clothing.,Do not apply to the genitals or scrotum.,Do not shower or swim for at least 3-4 hours after application.,Monitor for signs of skin irritation, such as redness or itching.,Report any swelling of the ankles, difficulty breathing, or changes in mood or sleep.,Keep the medication away from children and pets.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APALUTAMIDE vs ANDRODERM, answered by our medical review team.
APALUTAMIDE is a Androgen Receptor Inhibitor that works by Apalutamide is a nonsteroidal antiandrogen that inhibits androgen receptor (AR) nuclear translocation, DNA binding, and transcription of AR target genes. It also decreases AR-mediated tumor cell proliferation and increases apoptosis.. ANDRODERM is a Androgen that works by Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APALUTAMIDE and ANDRODERM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APALUTAMIDE is: 240 mg orally once daily with or without food.. The standard adult dose of ANDRODERM is: Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APALUTAMIDE and ANDRODERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APALUTAMIDE is classified as Category C. Apalutamide is contraindicated in pregnancy. Based on its mechanism of androgen receptor inhibition, it may cause fetal harm, including feminization of male fetuses and development. ANDRODERM is classified as Category C. Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.